egtazic acid has been researched along with l 365260 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpini, G; Baiocchi, L; Chowdhury, U; Francis, H; Glaser, S; Kanno, N; LeSage, G; Phinizy, JL | 1 |
| Chung, JM; Rhim, H; Yang, YM | 1 |
2 other study(ies) available for egtazic acid and l 365260
| Article | Year |
|---|---|
Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Benzodiazepinones; Cell Division; Cholangiocarcinoma; Egtazic Acid; Enzyme Activation; Gastrins; Humans; Isoenzymes; Phenylurea Compounds; Protein Kinase C; Protein Kinase C-alpha; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Tumor Cells, Cultured | 2001 |
Cellular action of cholecystokinin-8S-mediated excitatory effects in the rat periaqueductal gray.
Topics: Animals; Benzodiazepinones; Egtazic Acid; Excitatory Postsynaptic Potentials; Patch-Clamp Techniques; Periaqueductal Gray; Phenylurea Compounds; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Sincalide; Synaptic Transmission; Thapsigargin | 2006 |